Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
201
Active:7
Completed:13
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:27
Phase 2:100
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (170 trials with phase data)• Click on a phase to view related trials
Phase 2
100 (58.8%)Not Applicable
29 (17.1%)Phase 1
27 (15.9%)Phase 3
8 (4.7%)Phase 4
4 (2.4%)Early Phase 1
2 (1.2%)Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Not Applicable
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 812
- Registration Number
- NCT07057427
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Not Applicable
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT07047755
Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study
Recruiting
- Conditions
- Breast Cancer Patients
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT07037576
- Locations
- 🇨🇳
Henan cacer hospital, Henan, Henan, China
Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation
Not Applicable
Recruiting
- Conditions
- Breast Cancer Patients
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT07037537
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Breast CancerHR+/HER2- Breast Cancer
- Interventions
- Drug: Nab-PE
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 238
- Registration Number
- NCT06967103
- Prev
- 1
- 2
- 3
- 4
- 5
- 40
- Next
News
Immunotherapy-Enhanced Total Neoadjuvant Therapy Shows Promise for Locally Advanced Rectal Cancer
Two multi-institutional studies demonstrate that combining immune checkpoint inhibitors with total neoadjuvant therapy (TNT) achieves superior pathological complete response rates compared to standard chemoradiotherapy in microsatellite stable locally advanced rectal cancer patients.